News from Karo Pharma

26 September, 2022

Karo Intressenter AB initiates compulsory redemption

On 16 August 2022, Karo Intressenter AB[1] (“Karo Intressenter”) announced a public cash offer to the shareholders in Karo Pharma Aktiebolag (“Karo Pharma” or the “Company”) to acquire the shares in Karo Pharma not already held by Karo Intressenter at a price of SEK 60 per share (the “Offer”). On 19 September 2022, Karo Intressenter...

26 August, 2022

Karo Pharma Aktiebolag comments on the public offer from Karo Intressenter AB and obtains a fairness opinion

Background On 16 August 2022, Karo Intressenter AB1 (“Karo Intressenter”) announced a public cash offer to the shareholders in Karo Pharma Aktiebolag (“Karo Pharma”) to acquire the shares in Karo Pharma not already held by Karo Intressenter (the “Offer”) at a price of SEK 60 per share (the “Consideration”). As of the date of this...

16 August, 2022

Comment from Karo Pharma Aktiebolag’s board of directors regarding the public offer from Karo Intressenter AB

Today, on 16 August 2022, Karo Intressenter AB1 (“Karo Intressenter”) announced a public cash offer to the shareholders in Karo Pharma Aktiebolag (“Karo Pharma”) to acquire the shares in Karo Pharma not already held by Karo Intressenter at a price of SEK 60 per share (the “Offer”). For further information about the Offer, please refer...

21 July, 2022

Interim report H1 2022

January – June · Revenues amounted to MSEK 1 965.3 (1 460.9), corresponding to an increase of +35% for the period.· The organic growth1 during the period was +6%. The currency impact was +3% while the acquisitions of the Sylphar Group and E45® brand portfolio from Reckitt generated growth of +26%.· EBIT (Operating Profit) amounted...

19 April, 2022

Karo Pharma’s rights issue fully subscribed

Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore, the United States or any other jurisdiction in which the distribution or release would be unlawful or require further registration measures. This press release does not constitute an offer of any securities of Karo Pharma Aktiebolag. See the section “Important information” below.

12 April, 2022

Karo Pharma publishes the 2021 annual report

Today, on 12 April 2022, Karo Pharma is publishing its annual report for 2021 on the company’s website, www.karopharma.com. For further information, please contact: Lisa Westerdahl, Head of Corporate Communication, 073-329 70 04, lisa.westerdahl@karopharma.com Jon Johnsson, CFO, 073-507 88 61, jon.johnsson@karopharma.com The Annual Report is published in Swedish and English. The Swedish version represents the...

1 April, 2022

Karo Pharma completes the acquisition of the E45® brand from Reckitt

Karo Pharma Aktiebolag (“Karo”) has today completed the previously announced acquisition of the skin health brand, E45®, from Reckitt for a total consideration of GBP 200m. All conditions to the completion of the transaction have been satisfied. 

23 March, 2022

Karo Pharma publishes prospectus relating to the rights issue and receives approval to change listing venue to Nasdaq First North Growth Market

Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore, the United States or any other jurisdiction in which the distribution or release would be unlawful or require further registration measures. This press release does not constitute an offer of any securities of Karo Pharma Aktiebolag. See the section “Important information” below.

16 March, 2022

Karo Pharma resolves on a fully guaranteed rights issue of approximately SEK 2.5 billion and announces the terms of the rights issue

Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore, the United States or any other jurisdiction in which the distribution or release would be unlawful or require further registration measures. This press release does not constitute an offer of any securities of Karo Pharma Aktiebolag. See the section “Important information” below.

10 March, 2022

Karo Pharma receives approval to delist the Company’s share from Nasdaq Stockholm in connection with the change of listing venue to Nasdaq First North Growth Market

Karo Pharma Aktiebolag (publ) (the “Company” or ”Karo Pharma”) announced in a press release on 9 March 2022 that Karo Pharma’s Board of Directors has decided to apply for delisting of the Company’s share from Nasdaq Stockholm as well as listing on Nasdaq Stockholm First North Growth Market, and that the application on delisting had...

9 March, 2022

Karo Pharma applies for delisting of the Company’s shares from Nasdaq Stockholm, in connection with the change of listing venue to Nasdaq First North Growth Market

The Board of Directors of Karo Pharma Aktiebolag (publ) (the “Company” or “Karo Pharma”) has today decided to apply for and submitted the application regarding delisting of the Company’s shares from Nasdaq Stockholm as well as decided to apply for listing of the Company’s shares on Nasdaq First North Growth Market (the “First North-listing”).

25 February, 2022

Year-end report 2021

Q4, October – December · Revenues amounted to MSEK 762.0 (721.2), corresponding to an increase of +6% for the period.· The organic growth1 during the fourth quarter was +9%. The currency impact in the quarter was 1% while the acquisitions adjusted for the divestments generated a net effect of -5%.· EBIT (Operating Profit) amounted to...

13 January, 2022

Karo Pharma completes the acquisition of Sylphar International NV

Karo Pharma Aktiebolag (“Karo”) today announces that the previously announced acquisition of the Belgian fast-growing digital-first brand company Sylphar International NV (“Sylphar”) for EUR 290m has been successfully completed according to plan. The transaction is expected to contribute positively to Karo’s market position and further enhance Karo’s strong platform for continued growth, particularly in the...